Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3011441 in Japanese Patients with Advanced KRAS/NRAS Mutation Positive Solid Tumors
NCT04742556Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 3011441 in solid tumor (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Patients With Dose Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Started Mar 2021; status: completed.
02
Drugs
BI 3011441
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04742556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742556.